On March 19, 2026, LivaNova announced that the FDA granted premarket approval for its aura6000 System, a proximal hypoglossal ...

LivaNova PLC (NASDAQ:LIVN) is one of the 12 Best UK Stocks to Buy According to Hedge Funds. On March 19, 2026, LivaNova PLC ...

Device will not carry concentric collapse contraindication or warning language ...

Please provide your email address to receive an email when new articles are posted on . Those with vs. without severe obstructive sleep apnea faced an 87% greater risk for being hospitalized with ...

Medically reviewed by Smita Patel, DO Key Takeaways Obstructive sleep apnea is a chronic sleep disorder characterized by ...

Millions of people in the U.S. have sleep apnea, most of whom aren’t getting treated for it. But a simple daily pill of an old drug just might help people with the condition, recent trial data shows.

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA). On Dec. 20, the FDA announced that the agency has approved Eli Lilly’s Zepbound ...

Please provide your email address to receive an email when new articles are posted on . Individuals with moderate to severe obstructive sleep apnea had increased odds of having neovascular AMD.

Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing combination therapies for high-impact indications, today announced it has entered into a Partnership ...

In much the same way that they’re designed to expand wearers’ upper airways, Vivos Therapeutics’ slate of oral appliances have now expanded their FDA indications, too. Collectively known as the ...

The Food and Drug Administration (FDA) has approved Zepbound ® (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea (OSA) in adults with obesity. Zepbound is a dual ...

Obstructive sleep apnea was common in never-smokers with lung cancer. Read more about the prospective findings.